|
1. BIOLOGIE
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
Lung cancer screening complications may be higher than expected [Reuters]
|
|
|
|
|
|
Overall, about 22 percent of patients under 65 in the study had complications, as did almost 24 percent of the older people in the study. These complication rates are more than twice as high as those reported in the pivotal 2011 LDCT lung cancer screening study responsible for current screening recommendations, researchers report in JAMA Internal Medicine.
|
|
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
Aslan fails to roar as lead drug flunks phase 2 trial [Fierce Biotech]
|
|
|
|
|
|
The Singapore biotech says its phase 2 study of varlitinib as a first-line therapy for patients with HER1/HER2 co-expressing advanced or metastatic gastric cancer showed that the drug provided no additional benefit when added to standard chemotherapy when it came to shrinking tumors.
|
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
|
Highly mutated cancers respond better to immune therapy [Nature]
|
|
|
|
|
|
Ultimately, Shibutani suspects that it will take a combination of characteristics, including mutation counts and information about the concentration of a given protein to select patients for immunotherapy. “This is the exact opposite of ‘keep it simple, stupid’,” he says. “Naturally, there’s more work to be done."
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2 PHARMA
|
|
|
Sean Bohen to leave AstraZeneca as exodus continues [Fierce Biotech]
|
|
|
|
|
|
This comes amid a mixed time for AstraZeneca, with its CEO Pascal Soriot also endlessly speculated to be heading for the exit, something however he continuously denies, and a plethora of trial setbacks over the years, with cancer becoming a brighter spot but still being hit by some late-stage failures.
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Think Generics Will Lower the Cost of Chemo? Think Again [Forbes]
|
|
|
|
|
|
From the time it entered the market in 2001, until its last year of exclusivity, the price of Gleevec more than doubled. After a decade and a half of generating profits, Gleevec finally faced generic competition in 2016. But here is the rub: the price of the generic medicine was barely lower than the brand drug.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
You’re Not Getting Much Taller, America. But You Are Getting Bigger. [NY Times]
|
|
|
|
|
|
Meet the average American man. He weighs 198 pounds and stands 5 feet 9 inches tall. He has a 40-inch waist, and his body mass index is 29, at the high end of the “overweight” category. The picture for the average woman? She is roughly 5 feet 4 inches tall, and weighs 171 pounds, with a 39-inch waist. Her B.M.I. is close to 30.
|
|
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
|
|
|
How online crowdfunding supports cancer quacks (part 2) [Respectful Insolence]
|
|
|
|
|
|
In response to The Good Thinking Society’s report, GoFundMe claimed that it was already “taking proactive steps” in the US to make sure users of its site are better informed and will be doing the same globally over the coming months. However, I’ve seen no evidence thus far that GoFundMe has done a thing since September.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
Plan S: What About Researchers? [The Scholarly Kitchen]
|
|
|
|
|
|
The problem here for researchers is that they are being asked not just to make their article OA, but also to withdraw support for anything that may be connected to a subscription model – this is an authoritarian move, and restricts author choice.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|